for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Relief Therapeutics And Neurorx Enroll First Patients With RLF100 In Phase 2B/3 Clinical Trial

June 2 (Reuters) - RELIEF THERAPEUTICS HOLDING SA:

* RELIEF THERAPEUTICS AND NEURORX ANNOUNCE ENROLLMENT OF FIRST PATIENTS WITH RLF100 IN PHASE 2B/3 CLINICAL TRIAL IN PATIENTS WITH COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS

* CLINICAL TRIAL TO ENROLL 144 PATIENTS TOTAL

* PRIMARY ENDPOINTS WILL BE MORTALITY AND INDEX OF RESPIRATORY DISTRESS

* SECONDARY ENDPOINT WILL INCLUDE LEVELS OF TNFA AND MULTI-SYSTEM ORGAN FAILURE FREE DAYS Source text: bit.ly/2XXNbdM Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up